BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8650849)

  • 1. [Positron emission tomography in diagnosis of renal cell carcinoma].
    Bachor R; Kotzerke J; Gottfried HW; Brändle E; Reske SN; Hautmann R
    Urologe A; 1996 Mar; 35(2):146-50. PubMed ID: 8650849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
    Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
    Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
    Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
    J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lymph node staging of bladder neck carcinoma with positron emission tomography].
    Bachor R; Kotzerke J; Reske SN; Hautmann R
    Urologe A; 1999 Jan; 38(1):46-50. PubMed ID: 10081101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of FDG-PET in the evaluation of urologic malignancies.
    Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
    Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I; Can C
    Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
    Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
    Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating solitary pulmonary metastases in patients with renal cell carcinomas by 18F-fluoro-2-deoxyglucose positron emission tomography--a preliminary report.
    Chang CH; Shiau YC; Shen YY; Kao A; Lin CC; Lee CC
    Urol Int; 2003; 71(3):306-9. PubMed ID: 14512653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT.
    Thambugala GM; Mohamed A; O' Neill GF; Fulham MJ
    Australas Radiol; 2006 Dec; 50(6):604-6. PubMed ID: 17107535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera.
    Montravers F; Grahek D; Kerrou K; Younsi N; Doublet JD; Gattegno B; Rossert J; Costa de Beauregard MA; Thibault P; Talbot JN
    J Nucl Med; 2000 Jan; 41(1):78-84. PubMed ID: 10647608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Validity of positron emission tomography (PET) using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in patients with renal cell carcinoma (preliminary report)].
    Kawamura J; Hida S; Yoshida O; Yonekura Y; Senda M; Yamamoto K; Saji H; Fujita T; Konishi J
    Kaku Igaku; 1988 Oct; 25(10):1143-8. PubMed ID: 3265450
    [No Abstract]   [Full Text] [Related]  

  • 14. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
    Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary synovial sarcoma of the kidney: use of PET/CT in diagnosis and follow-up.
    Erturhan S; Seçkiner I; Zincirkeser S; Erbagci A; Celik M; Yagci F; Karakok M
    Ann Nucl Med; 2008 Apr; 22(3):225-9. PubMed ID: 18498039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas.
    Laubenbacher C; Saumweber D; Wagner-Manslau C; Kau RJ; Herz M; Avril N; Ziegler S; Kruschke C; Arnold W; Schwaiger M
    J Nucl Med; 1995 Oct; 36(10):1747-57. PubMed ID: 7562038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare presentation of metastatic renal clear cell carcinoma to the tongue seen on FDG PET.
    Basely M; Bonnel S; Maszelin P; Verdalle P; Bussy E; de Jaureguiberry JP
    Clin Nucl Med; 2009 Sep; 34(9):566-9. PubMed ID: 19692815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in a patient affected by renal collecting duct (Bellini) carcinoma.
    Bertagna F; Fisogni S; Tardanico R; Simeone C; Cunico SC; Giubbini R
    Clin Nucl Med; 2012 Oct; 37(10):986-8. PubMed ID: 22955073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated positron emission tomography and computed tomography in preoperative lymph node staging of non-small cell lung cancer.
    Xu N; Wang M; Zhu Z; Zhang Y; Jiao Y; Fang W
    Chin Med J (Engl); 2014; 127(4):607-13. PubMed ID: 24534208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.